An Exploratory Study of Sleep-Wake Differences of Autonomic Activity in Patients with Mild Cognitive Impairment: The Role of Melatonin as a Modulating Factor

Clin Interv Aging. 2023 May 12:18:771-781. doi: 10.2147/CIA.S394749. eCollection 2023.

Abstract

Purpose: The objective of the present study was to assess sleep-wake differences of autonomic activity in patients with mild cognitive impairment (MCI) compared to control subjects. As a post-hoc objective, we sought to evaluate the mediating effect of melatonin on this association.

Patients and methods: A total of 22 MCI patients (13 under melatonin treatment) and 12 control subjects were included in this study. Sleep-wake periods were identified by actigraphy and 24hr-heart rate variability measures were obtained to study sleep-wake autonomic activity.

Results: MCI patients did not show any significant differences in sleep-wake autonomic activity when compared to control subjects. Post-hoc analyses revealed that MCI patients not taking melatonin displayed lower parasympathetic sleep-wake amplitude than controls not taking melatonin (RMSSD -7 ± 1 vs 4 ± 4, p = 0.004). In addition, we observed that melatonin treatment was associated with greater parasympathetic activity during sleep (VLF 15.5 ± 0.1 vs 15.1 ± 0.1, p = 0.010) and in sleep-wake differences in MCI patients (VLF 0.5 ± 0.1 vs 0.2 ± 0.0, p = 0.004).

Conclusion: These preliminary findings hint at a possible sleep-related parasympathetic vulnerability in patients at prodromal stages of dementia as well as a potential protective effect of exogenous melatonin in this population.

Keywords: actigraphy; circadian rhythms; heart rate variability; wavelets.

MeSH terms

  • Actigraphy
  • Circadian Rhythm / physiology
  • Cognitive Dysfunction* / complications
  • Cognitive Dysfunction* / drug therapy
  • Humans
  • Melatonin* / pharmacology
  • Melatonin* / therapeutic use
  • Sleep / physiology
  • Sleep Wake Disorders* / drug therapy

Substances

  • Melatonin